De-Risking Investments in Medical Technology Innovation: Strengthening Decision-Making and Valuation Accuracy in Medical Startups
暫譯: 降低醫療科技創新投資風險:加強醫療初創企業的決策與估值準確性

Negri, Luigi

  • 出版商: Springer
  • 出版日期: 2026-04-17
  • 售價: $5,220
  • 貴賓價: 9.5$4,959
  • 語言: 英文
  • 頁數: 2
  • 裝訂: Hardcover - also called cloth, retail trade, or trade
  • ISBN: 303215006X
  • ISBN-13: 9783032150066
  • 相關分類: 投資理財 Investment
  • 海外代購書籍(需單獨結帳)

商品描述

This book provides medical technology entrepreneurs and their investors with a decision-making methodology based on the scientific approach that maximizes their chances of success. It enriches the understanding of valuation for medical startups, proposing an approach that moves the focus from the sophistication of the forecasting and financial methodologies to the quantitative importance of high-quality business assumptions and the economic impact of each critical business decision. It also provides a complete set of visual, organized, and compelling mental maps tailored to the business of medical technology innovation; maps that visualize and link the medical venture's decision-making and prediction problems. Their use minimizes the probability of overlooking critical decision problems on the path to successful execution while connecting them through a sequential and hierarchical framework. Finally, the book provides practical, real-life examples of how the scientific approach to decision-making can be used in medical technology startups outside the clinical trial area. The reader is left with various sets of valuable and practical tools that can be individually applied.

商品描述(中文翻譯)

本書為醫療科技創業者及其投資者提供了一種基於科學方法的決策制定方法論,以最大化他們成功的機會。它豐富了對醫療初創企業估值的理解,提出了一種方法,將重點從預測和財務方法的複雜性轉移到高品質商業假設的定量重要性以及每個關鍵商業決策的經濟影響上。它還提供了一整套視覺化、組織化且引人入勝的思維導圖,專為醫療科技創新業務量身定制;這些導圖可視化並連結醫療創業的決策制定和預測問題。其使用可最小化在成功執行過程中忽視關鍵決策問題的可能性,同時通過一個連續且分層的框架將它們連接起來。最後,本書提供了實用的現實生活範例,展示了科學決策方法如何在臨床試驗領域以外的醫療科技初創企業中應用。讀者將獲得各種有價值且實用的工具集,這些工具可以單獨應用。

作者簡介

Dr Luigi Negri is Founder and CEO for ThinKeen(R) Global Consulting (Miami, FL, USA) and Venture Partner of Obloo(R) Ventures Consulting (Milano, Italy). In this role, he has supported investors in the appraisal and valuation of target medical startups, he has been a board member of highly innovative medical startups and served as a member of advisory boards of broader public initiatives focused on evaluating larger populations of life science startups. In the previous twenty years, Luigi has succeeded as an executive in several international corporate assignments with general management responsibilities in the biotechnology and medical devices industry across multiple global corporations and geographical regions. These positions included VP of Northern & Central Europe for Becton Dickinson(R) (CR Bard), VP of Emerging Markets of Latin America at Baxter Health Care, and Area General Manager for Poland & Russian Federation at Baxter Health Care(R).

作者簡介(中文翻譯)

盧伊吉·內格里博士是ThinKeen(R) Global Consulting(美國邁阿密)的創辦人兼首席執行官,以及Obloo(R) Ventures Consulting(意大利米蘭)的風險合夥人。在這個角色中,他支持投資者對目標醫療初創公司的評估和估值,並且曾擔任多家高度創新的醫療初創公司的董事會成員,還擔任過針對評估更大規模生命科學初創公司的公共倡議的諮詢委員會成員。在過去的二十年中,盧伊吉在多家全球企業和地理區域的生物技術和醫療設備行業中,成功擔任多個國際企業任務的高管,負責一般管理職責。這些職位包括Becton Dickinson(R)(CR Bard)北歐及中歐副總裁、Baxter Health Care拉丁美洲新興市場副總裁,以及Baxter Health Care(R)波蘭及俄羅斯聯邦區域總經理。